In a subsequent analysis of the WELCOME trial, it appeared that the PNPLA3 148MM variant that was present in about 20 % of recruited NAFLD patients influenced the effect of n-3 fatty acid treatment and in this post hoc analysis was associated with an attenuated impact of the fatty acid treatment(92). Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.